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Background: Non-mucinous bronchioloalveolar carcinoma (BAC) is considered the early stage of lung
adenocarcinoma and is classified as the lung adenocarcioma in situ (AIS) by the International Association for the
Study of Lung Cancer/American Thoracic Society/European Respiratory Society. This study was designed to
investigate the gene expression differences between AIS (formerly non–mucinous BAC) and invasive lepidic
predominant adenocarcinoma (LPA, formerly non-mucinous BAC pattern with >5 mm invasion, mixed type
adenocarcinoma with BAC features) and to investigate the mechanism of the progression of lung adenocarcinoma
in situ to invasive adenocarcinoma.
Methods: Gene expression analysis was performed by using Agilent 4 × 44 K Whole Human Genome Oligo
Microarray on 10 fresh frozen tissue samples of AIS and LPA, respectively. Real time RT-PCR was used to validate the
differential expression of 13 genes selected by cDNA microarray on fresh frozen tissue samples from 41 patients
with lung adenocarcinoma and 4 genes were confirmed. These 4 genes were then validated by western blotting.
Immunohistochemical staining for these validated genes was performed on formalin-fixed, paraffin-embedded
tissue samples from 81 cases of lung adenocarcinomna.
Results: We identified a 13 gene expression signature by comparative analysis of gene expression. Expression of
these genes strongly differed between AIS and LPA. Four genes (MMP-2, c-fos, claudin 1 (CLDN1) and claudin 10
(CLDN10)) were correlated with the results of microarray and real time RT-PCR analyses for the gene-expression
data in samples from 41 patients with lung adenocarcinoma. As confirmed by western blotting, the expression
levels of MMP-2 and c-fos were higher in LPA than those in AIS; the expression levels of CLDN1 and CLDN10 in LPA
were lower than those in AIS. Immunohistochemical staining for these genes in samples from 81 cases of lung
adenocarcinoma demonstrated the expressions of CLDN1 and CLDN10 were correlated with overall survival of
patients with lung adenocarcinoma.
Conclusions: CLDN1 and CLDN10 may play important roles in the development of AIS to LPA. Overexpression of
CLDN1 and CLDN10 indicates a favorable prognosis for overall survival in some patients with lung adenocarcinoma.
Expression of CLDN10 may be regulated by the c-fos pathway.
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Table 1 Clinical features of AIS and LPA in the cohort1
and 2
Factors c1 c2
AIS LPA AIS LPA
Sex
Male 7 2 5 13
Female 3 8 11 12
Age
≤60 3 3 7 4
>60 7 7 9 21
Smoking
No 9 8 16 12
Yes 1 2 0 13
Location
Peripheral 10 8 16 19
Central 0 2 0 6
Surgical procedure
Lobectomy 10 10 16 24
Pneumonectomy 0 0 0 1
laterality
Left 5 4 10 9
Right 5 6 6 16
p N status
N0 10 10 16 16
N1 0 0 0 6
N2 0 0 0 3
pT status
T1 10 8 16 15
T2-3 0 2 0 10
c1: Clinical-pathological characteristics of the 10 patients with AIS and LPA
used for cDNA microarray analysis.
c2: Clinical-pathological characteristics of the 41 patients in the
validation cohort.
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Liebow first coined the term bronchioloalveolar carcinoma
(BAC) in 1960, describing the tumor as a well-differentiated
adenocarcinoma with neoplastic cells spreading along
alveoli with little stromal reaction, no invasion, and preser-
vation of alveolar architecture [1]. Based on the 2004 WHO
classification guidelines [2], BAC has a distinct histological
pattern of tumor cells growing along preexisting alveolar
framework without evidence of stromal, pleural, or vascu-
lar invasion. However, a new international multidiscip-
linary classification was sponsored by the International
Association for the Study of Lung Cancer, American
Thoracic Society, and European Respiratory Society and
non-mucinous BAC (≤3 cm) is classified as adenocarcin-
oma in situ (AIS) [3]. Some authors suggested that atypical
adenomatous hyperplasia (AAH), adenocarcinoma in situ
(formerly pure BAC), Minimally invasive adenocarcinoma
(formerly BAC with focal invasion), invasive lepidic pre-
dominant adenocarcinoma (LPA, formerly adenocarcinoma
with BAC features, invasive adenocarcinoma) might repre-
sent the developmental sequence of bronchioloalveolar
stem cells rather than a classification system [4,5]. Stepwise
progression from AAH through AIS to LPA was thus pro-
posed. We made a hypothesis that there are some abnormal
genes expressed in the progression from AIS to LPA, and
these genes may be related with the poor prognosis of some
patients with lung adenocarcinoma. In this study, we used
gene microarrays to explore the differentially expressed
genes between AIS and LPA. To our knowledge, it was the
first study to investigate the roles of genes in the develop-
ment of AIS to LPA.
Methods
The lung cancer tissues analyzed in cDNA microarray
study were obtained from the collection of fresh frozen
lung cancer tissues in the tissue bank of Cancer Institute
and Hospital, Tian Jin Medical University, Tian Jin, P.R.
China, collected between 2000 and 2005. For the pur-
pose of this study, 10 AIS and 10 LPA tissue samples
were evaluated. The ethics committee of the university
approved this study, and all patients participating in the
study consented to sampling. Only tumor samples with
neoplasticity of greater than 85% were included in
the analysis. For each case, the histology slides were
reviewed independently by two pathologists and tumors
were classified according to the new IASLC classification
system [3]. Clinical characteristics of the samples were
provided in Table 1.
In order to validate the selected genes, we studied fro-
zen specimens of lung-cancer tissues from 41 randomly
selected patients with lung adenocarcinoma who under-
went surgical resection at the Tianjin Medical University
Cancer Institute & Hospital. None of the patients re-
ceived the neoadjuvant chemotherapy (Table 1).81 paraffin-embedded tissues of lepidic predominant
adenocarcinoma (LPA) were obtained from Tianjin Cancer
Institute & Hospital, Tianjin Medical University, Tianjin,
China. Patient medical records were retrospectively
reviewed to assess clinical characteristics and survival.
There were 30 (37.0%) males and 51 (63.0%) females with
ages ranging from 32 to 78 years, and a median age of 61 -
years. Those who had smoked <100 cigarettes in their life-
times were defined as never smokers as traditionally used
in epidemiological studies, while the remaining cases were
considered as smokers. The routine preoperative workup
included contrast CT scans of the chest, whole body bone
scanning, liver sonography, flexible bronchoscopy, and
brain magnetic resonance imaging. 16 patients underwent
PET-CT scans. In our hospital, if a contrast CT or PET-
CT showed no mediastinal lymph node enlargement, a
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tinely performed. 9 patients in our study underwent
mediastinoscopy. No neoadjuvant therapy was applied to
any of the 81 patients. All these patients had systematic
lymph node dissection or sampling performed. Prior con-
sents from the patients and approval from the Research
Ethics Committee of Tianjin Cancer Institute & Hospital
of Tianjin Medical University were obtained. Histological
classification of the samples was graded according to the
WHO histologic classification. Clinicopathological vari-
ables were summarized in Table 2.
We recommended that patients have follow-up visits
every 3 months for 2 years, then visits every 6 months for
3 years and then annual visits. All patients were followed
up until death or the last day of follow-up (December 31,
2010). The median length of follow-up for surviving pa-
tients was 57 months (range, 9–101 months).
Follow-up information was obtained either from hos-
pital case records, or a questionnaire completed by the
chest physician or general practitioner via telephone or
mail, or from death certificates. The follow-up protocol in-
cluded physical examination of patients, tumor markers,
chest radiography, CT scanning of the chest, liver sonog-
raphy, and whole body bone scanning. Overall survival
was measured from the date of operation until the date of
death. Patients who died of other causes without evidence
of recurrent disease or who were unavailable for follow-up
were censored either at the time of death or at the last
follow-up.
Microarray analysis
RNAs from 10 AIS and 10 LPA were extracted withTRIZOL
reagent (Invitrogen, MD, USA) and purified with RNeasy
MINI Kit (Qiagen, CA, USA) according to the manufac-
turer’s instructions. All samples included for analysis were
determined to be of high quality RNA (OD260/280 = 1.9–
2.1. NANODROP 2000c, Gene Company Limited). Low
RNA Input Fluorescent Linear Amplification Kits (Agilent
Technologies) were used to generate fluorescently labeled
cRNA. Briefly, MMLV-Reverse transcriptase and dT-T7
primer were used to amplify mRNA from total RNA sam-
ples into dsDNA. Cyanine 3-labeled cRNA was produced
using T7 polymerase. The labeled cRNA was purified using
RNeasy Mini kits and concentration was measured using a
spectrophotometer. cRNA (875 ng) was fragmented for
30 min at 60°C and subsequently hybridized to 4x44K
Whole Human Genome Oligo Microarray chip (Agilent
Technologies) in stainless steel hybridization chambers.
Hybridization was carried out over 17 h in the dark in a ro-
tating hybridization chamber set at 60°C and 4 rpm. After
hybridization, slides were washed in Gene Expression
Wash Buffer 1 and 2 for 1 min and then dried by centrifu-
gation at 2000 rpm for 2 min. Microarrays were scanned
with a dynamic autofocus microarray scanner (AgilentMicroarray Scanner- G2565AA, Agilent Technologies,)
using Agilent-provided parameters (PMT was set at 100%,
and scan resolution was set to 5 μm). The Agilent Feature
extraction software (FE) (Agilent Technologies) was used
to extract and analyze the signals. This software calculates
log ratios and p-values for valid features on each array and
provides a confidence measure of gene differential expres-
sion performing outlier removal and background subtrac-
tion. Furthermore, FE filters features that are not positive
or significant with respect to background or are saturated.
FE was also used to perform linear and LOWESS dye
normalization to correct dye bias. The raw data and associ-
ated sample information were loaded and processed by
GeneSpringW 10 (Agilent Technologies). Statistical analysis
was performed using background-corrected mean signal
intensities from each dye channel. Microarray data were
normalized using intensity-dependent global normalization
(LOWESS). Differentially expressed RNAs were identified
using a filtering by the Benjamini and Hochberg False
Discovery Rate (p < 0.05) to minimize selection of false
positives. Of the significantly differentially expressed
RNA, only those with greater than 5-fold increase or 5-
fold decrease in expression compared to the controls
were used for further analysis. We identified 353 up- and
187 down-regulated genes from Agilent 4x44K Whole
Human Genome Oligo Microarray.Quantitative real-time reverse transcription-PCR
To validate the expression levels of genes found on micro-
array analysis, real-time RT-PCR was performed on 13
genes and the control gene GAPDH, with the use of specific
TaqMan probes and primer sets (Table 3). The transcripts
were amplified with reagent (TaqMan One-Step RT-PCR
Master Mix Reagent, Applied Biosystems) and a sequence
detection system (ABI Prism 7900HT, Applied Biosystems).
Gene expression was quantified in relation to the expression
of GAPDH using sequence detector software with the rela-
tive quantification method (Applied Biosystems).
Western blotting
In brief, 100 mg frozen tissue was homogenized, and ex-
tracts were centrifuged at 10,000 g for 5 minutes at 4°C to
remove debris. Then, 10 uL supernatant was heated in a
boiling water bath for 4 minutes and subjected to sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis.
The electrotransfer of proteins from the gel to a nitrocel-
lulose membrane was performed for 30 minutes using a
semidry transfer system (BioRad, Hercules, CA). The
membrane was then soaked in 5% defatted dry milk di-
luted with phosphate-buffered saline containing 0.02%
Tween20 to reduce nonspecific protein binding. Next, the
membrane was incubated with 50 uL antibody (MMP-2,
c-fos: Santa Cruz Biotechnology, Inc, Santa Cruz, CA;






Male 30 54.73 0.7494
Female 51 46.43
Smoking
No 53 56.39 0.1286
yes 28 40.56
Proportion of lepidic growth (BAC) in
adenocarcinoma*
≤50% (including 0%) 50 35.69 0.0375
>50% 31 58.32
Age
≤60 years 25 52.85 0.6028
>60 years 56 47.74
Location
Central 7 42.86 0.2521
Peripheral 74 50.47
Staging




T1 43 60.63 0.0142
≥T2 38 43.38
N stage







Left 38 52.12 0.2873
Right 43 48.29
ECOG performance status
0 75 50.83 0.4872
1 6 49.15
Histologic differentiation
Well 58 60.37 0.0089
Moderate/poorly 23 41.28
Claudin 1
- 33 26.75 0.0034
+ 48 63.20
Table 2 Factors and prognosis of patients with LPA by
Univariate Analysis (Continued)
c-fos
- 28 55.19 0.8438
+ 53 29.43
Claudin 10
- 25 30.30 0.0019
+ 56 59.75
MMP-2
- 19 12.00 0.3208
+ 62 41.81
Combination of CLDN1&CLDN10
both factors expressed 35 68.90 0.0000
either factor expressed 35 44.32
neither factor expressed 11 0
*: We defined 50% as a cutoff for lepidic growth in these tumors because
some studies showed that if the lepidic growth was more than 50%, the
5-year survival of patients with T1 lung adenocarcinoma was much better than
those with less than 50% lepidic growth [6-9].
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CA) for 45 minutes at room temperature and then treated
with a suitable second antibody for 30 minutes at room
temperature. Enhanced chemiluminescence analysis was
performed according to the manufacturer’s instructions,
and the image was developed in a film in a darkroom.Immunohistochemistry
Paraffin sections (4 μm) from samples were deparaffinized
in 100% xylene and re-hydrated in descending ethanol di-
lutions according to standard protocols. Heat-induced
antigen retrieval was performed in EDTA buffer (pH 9.0)
for 3 min at 100°C. Endogenous peroxidase activity and
non-specific antigens were blocked with peroxidase
blocking reagent containing 3% hydrogen peroxide and
serum, followed by incubation with each antibody over-
night at 4°C. After washing, the sections were incubated
with biotin-labeled secondary antibody for 40 min at 37°C,
and were subsequently incubated with streptavidin-
conjugated horseradish peroxidase (HRP). The peroxidase
reaction was developed using 3, 3-diaminobenzidine
chromogen solution in DAB buffer substrate (ChemMate
TM EnVision TM Detection Kit, Dako, USA). Sections
were visualized with DAB counterstained with hema-
toxylin, mounted in neutral gum, and analyzed using a
bright field microscope [10]. We counted 800 of the can-
cer cells. All immunostained sections were examined by at
least two pathologists. Positive staining was defined as the
presence of immunoreactivity in at least 10% of cancer
cells. We defined the 10% immunoreactivity of the immu-
nostained sections as the cut-off point arbitrarily.
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The average intensity for each gene in the microarray
was assessed. To reduce variation in microarray analysis,
the intensity values for samples in each microarray were
rescaled by means of a quantile normalization method
[11]. Each intensity value was then log-transformed to a
base-2 scale. Finally, the gene expression intensity values
were transformed to ordinal coding values, according to
the ranking of the level of gene expression among the
550 genes in 41 patients. The intensity value was coded
as 1 for expression levels ranked at or below the 25th
percentile of the total gene expression, 2 for levels above
the 25th and at or below the 50th percentiles, 3 for
levels above the 50th and at or below the 75th percen-
tiles, and 4 for levels above the 75th percentile. We used
univariate Cox proportional-hazards regression analysis
to evaluate the association between survival and the level
of expression of each gene from microarray analysis. For
genes that were significantly correlated with survival, we



























Reverse ACTGGCTGATGCTCCTTATTGThe x2 test was used to evaluate for associations be-
tween c-fos/MMP2 and CLDN1/CLDN10 expression.
Survival rates were calculated by the Kaplan-Meier
method. Comparisons were made with log-rank test, and
the Cox proportional hazards ratio model was used to
investigate the simultaneous effect of multiple predictors
on survival. All tests of significance were two-sided, and
differences were considered statistically significant at
p values less than 0.05. The SPSS software (version 10.0;
SPSS, Chicago, Illinois) was used for the analysis.
Results
1. c-fos, MMP-2,CLDN1 and CLDN10 were differently
expressed between AIS and LPA
To investigate the molecular factors associated with lung
adenocarcinoma development, we investigated gene expres-
sion changes between AIS and LPA. For this study, 10 AIS
and 10 LPA tissues were selected. The clinicopathologic
data were summarized in Table 1. Using stringent selection























Table 4 Validation of the 13 differentially expressed genes in 41 patients with AIS LPA
Gene name Fold regulation Up/down P※ HR Correlation coefficient▲ P*
claudin 7 (CLDN7) 0.0691 Down <0.01 0.432 0.68 <0.01
SMAD specific E3 ubiquitin-- protein ligase2 (SMURF2) 5.8528 Up <0.01 2.422 0.58 <0.01
claudin 1 (CLDN1) 0.0344 Down 0.001 1.731 0.44 <0.01
FBJ murine osteosarcoma viral oncogene homolog (c-fos) 7.8182 Up 0.02 0.75 0.64 <0.01
met-proto-oncogene (MET) 5.5674 Up <0.01 0.455 0.26 0.21
Vascular cell adhesion molecule 1 (VCAM1) 0.0593 Down <0.01 2.156 0.25 0.23
WNT inhibitory factor 1 (WIF1) 0.1727 Down <0.01 1.727 0.20 0.45
Fibroblast growth factor receptor 1 (FGFR1) 8.3246 Up 0.001 0.611 0.14 0.66
Wingless-typeMMTVintegrationsitefamilymember 2 (wnt 2) 6.1408 Up <0.01 0.497 0.18 0.68
Matrix metallopeptidase 2 (MMP-2) 9.6869 Up 0.038 1.321 −0.19 0.59
Suppressor of cytokinesignaling1 (SOCS1) 5.0212 Up 0.001 1.671 0.05 0.78
Mucin 4, cell surface associated (MUC4) 0.1278 Down 0.012 0.717 0.02 0.82
Sp1 transcription factor (sp1) 0.1567 Down 0.049 0.793 0.01 0.89
P※ values were estimated by univariate Cox regression analysis of the microarray data.
▲: Correlation Coefficient for Microarray Results vs. Real-Time RT-PCR Results.
P*values for the correlation coefficients were estimated by Spearman’s rank-correlation test.
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4x44K Whole Human Genome Oligo Microarray (data not
shown). The univariate Cox regression analysis showed
that the expression levels of 13 genes correlated with
disease-free survival of patients with lung adenocarcinoma
(Table 4). All 13 differentially expressed genes were chosen
for RT-PCR validation. There was a significant correlation
between the results of microarray and RT-PCR analyses for
the gene expression data for 4 of the 13 genes in samples
from 41NSCLC patients (Table 4). These four genes
including c-fos, MMP-2, CLDN1 and CLDN10 were
validated by western blotting (Figure 1). Both up- and
down- regulated genes were identified. The expression
levels of C-fos and MMP-2 were higher in LPA disease
than those in AIS; While the expression levels of CLDN1
and CLDN10 were lower in LPA.Figure 1 Expression of c-fos, MMP-2, claudin 1 and claudin 10
in AIS and LPA by Western blotting. The blots were subsequently
probed with anti-actin antibody as a loading control. 1: AIS:
adenocarcinoma in situ 2: LPA: lepidic predominant adenocarcinoma.Immunohistochemical analysis
In order to know whether the expression levels of these 4
genes had a prognostic value in lung adenocarcinoma, we
obtained the paraffin-embedded tissue blocks from 81
consecutive patients with adenocarcinonma for immuno-
histochemical staining. The expression of c-fos in most of
the cancer cells showed nuclear staining pattern (Figure 2)
and the nuclear positive rate was 62.2% (53/81). The
CLDN1 (Figure 3) and CLDN10 (Figure 4) showed the
membrane staining pattern, and the positive rate
was 59.3% (48/81) and 69.1% (56/81), respectively. The
MMP-2 showed membrane, cytoplasm and extracellular
space staining (Figure 5), and the positive rate was 76.5%
(62/81). The expression of claudin 10 was inversely related
with the expression of c-fos (Table 5).Predicting prognosis
Univariate analysis revealed that staging, the proportion of
lepidic growth (BAC) in adenocarcionma, lymph node
involvement, the expression of CLDN 1, CLDN 10 and
T stage (p = 0.0002, p = 0.0375, p = 0.0004, p = 0.0034,
p = 0.0019, p = 0.0142, respectively; Table 2) were prognos-
tic factors. Patients with positive expression of CLDN 1/
CLDN 10 had a survival significantly longer than those
with negative expression of these two factors (Figures 6
and 7). We made a survival analysis of the combination of
CLDN 1 and CLDN 10, and found that patients with posi-
tive expression of these two factors had a better 5-year
overall survival than those with either or neither expres-
sion of the factors (P = 0.0000, Figure 8). Table 6
Figure 4 Immunohistochemical staining of CLDN10 expression
in the lung adenocarcinoma tissues. CLDN10 showed membrane
staining pattern.
Figure 2 Immunohistochemical staining of c-fos expression in
the lung adenocarcinoma tissues. c-fos showed nuclear
staining pattern.
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of prognostic factors, which were determined by univar-
iate analysis (p <0.05), in overall survival in 81 patients.
In this study, staging (p = 0.004), lymph node involve-
ment (p = 0.024), T stage (p =0.041), CLDN 1 (p =0.038),
and CLDN 10 (p =0.029) were found to be related with
overall survival of patients with LPA.
Discussion
Literatures regarding the status of claudins in various can-
cers are constantly expanding, and the expression levels of
claudins seem to change in a tissue specific manner. Tan
et al. [13] showed that the expression and distribution of
claudin-1were associated with cell dissociation status in
pancreatic cancer cells through mitogen-activated proteinFigure 3 Immunohistochemical staining of CLDN1 expression
in the lung adenocarcinoma tissues. CLDN1 was expressed in the
cell membrane.kinase 2 activations. Claudin-7 was found to be decreased
in invasive ductal carcinomas [14], head and neck cancer
[15] and metastatic breast cancer [16]. Claudin-3 and −4
were frequently elevated in various cancers including pan-
creatic ductal adenocarcinoma [17], prostate, uterine,
ovarian cancer [18], while hepatocellular and renal carcin-
omas expressed lower levels of claudins-4 and −5 [19].
While, lower expression of claudin-2 was also seen in
breast and prostatic carcinomas, expressions of claudin1
and claudin7 that were undetectable in normal cervical
squamous epithelium increased in the cervical neoplasia
[19,20]. Recent studies have shown that the expression of
certain claudins especially claudin-1 and claudin-4 in-
creases during metastasis and genetic inhibition of their
expression has profound effect on the metastatic abilitiesFigure 5 Immunohistochemical staining of MMP-2 expression
in the lung adenocarcinoma tissues. MMP-2 was expressed in the
cell membrane, cytoplasm and extracellular space.
Figure 7 Relationship between expression of CLDN10 and
survival of patients with lung adenocarcioma. Patients with
positive CLDN10 expression had a better survival than those with
negative expression (P = 0.0019).
Table 5 The expressions of claudin1, claudin 10, c-fos and
MMP-2 in lung adenocarcinoma
Claudin1 p Claudin 10 p
+ − + −
c-fos
+ 28 25 0.105 30 23 0.001
- 20 8 26 2
MMP-2
+ 38 24 0.502 44 18 0.519
- 10 9 12 7
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mRNA and protein expressions of claudin-1 were found
to have prognostic values in lung adenocarcioma [22].
Our study found that the expressions of CLDN1 and
CLDN10 were higher in AIS than those in LPA. The
Cox proportional hazard models indicated that claudin
1 and claudin 10 were prognostic predicators. Our
results suggested that claudin 1 and claudin 10 may play
important roles in the progression of AIS to invasive
lung adenocarcinoma.
Decreased expressions of claudin 1 and claudin 10
might lead to the compromised tight Junctions’ function
and, thus, neoplasia progression was easy to comprehend.
Furthermore, it is postulated that claudins may also affect
cell signaling pathways. Cell-cell adhesion proteins are
known to play important role in cellular transformation
when displaced from their normal membrane localization
and can serve as oncogenic molecule. The best studied
molecule was β- catenin, which could serve as a cell-cell
adhesion molecule when expressed in its normal cellular
localization [25]. Expression of specific claudin familyFigure 6 Relationship between expression of CLDN1 and
survival of patients with lung adenocarcioma. Patients with
positive CLDN1 expression had a better survival than those with
negative expression (P = 0.0034).members could be regulated by Wnt signaling pathway.
Claudin-1 and claudin-2 were shown to be target genes
regulated by β-catenin signaling [26,27]. In our study, we
found the expression of claudin 10 was inversely related
with the expression of c-fos. c-Fos, a well-established onco-
gene, is considered to play a critical role in tumorigenesis,
proliferation and transformation, angiogenesis, tumor in-
vasion, and metastasis, and its expression is associated
with poor clinical outcomes, even though some studies
suggested that c-Fos might also have a proapoptotic role
[28,29]. Our study suggested that the expression of claudin
1(p = 0.105) and claudin 10(p = 0.027) may fuction asFigure 8 Patients with the expression of both CLDN 1 and
CLDN10 had a better 5-year overall survival than those with
either and neither expression of the two factors (P = 0.0000).
Both (+): Both CLDN 1 and CLDN10 were positively expressed.
Either (+): Either CLDN 1 or CLDN10 was positively expressed. Both
(−): Neither of the two factors was positively expressed.
Table 6 Factors and prognosis of patients with LPA by
Cox proportional hazards ratio model
Factors OR 95% CI p
Proportion of lepidic growth (BAC)
in adenocarcinoma
≤50% 0.513 0.256-0.834 0.098
>50%
Staging








T1 0.587 0.015-0.089 0.041
T2-3
Histologic differentiation
Well 0.382 0.009-0.765 0.035
Moderate/poorly
Claudin 1
+ 0.415 0.176-0.767 0.038
-
Claudin10
+ 0.352 0.165-0.867 0.029
-
CI: confidence interval; OR:odds ratio.
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adenocarcinoma through c-fos signal pathway.
Our study also found a higher expression of MMP-2 in
LPA, suggesting the role of MMP-2 in the development of
lung adenocarcinoma. Matrix metalloproteinases (MMP)
are a family of over 20 extracellular, zinc-dependent proteo-
lytic enzymes capable of degrading multiple components of
the extracellular matrix. These enzymes play important
roles not only in normal physiologic conditions, such as
matrix homeostasis, but also in pathologic processes, in-
cluding tumor progression where their expression is asso-
ciated with invasive and metastatic behavior [30,31]. Not
surprisingly, our study indicated that MMP-2 may play an
important role in the progression of lung adenocarcinoma.
Our study had some shortcomings: first, the number
of the patient samples was small. We just randomly se-
lected some patients for validation who had LPA and full
follow-up information, so the study may have the selec-
tion bias. Second, the cDNA microarray showed many
abnormally expressed genes between AIS and LPA di-
sease. We only selected 13 genes by our way of statisticalanalysis, and after validation, only 2 genes were proved
to have clinical significance. We have to admit that there
are some other genes that may have some clinical value,
even the other putative oncogenes and suppressor genes
in the 13 differentially expressed genes in our study are
likely to have a role. But the genes we selected were
proved to have some clinical significance in lung adeno-
carcinoma. We believe that the progress, invasion and
metastasis of lung adenocarcinoma are so complicated
that they cannot be explained clearly by a simple study.
Our results only provide a way to know the mechanism
of lung cancer cell developing and to predict prognosis
of lung adenocarcinoma, although it remains to be de-
termined through further studies.
Conclusions
Our study shows that CLDN1 and CLDN10 may play im-
portant roles in the development of AIS to LPA.
Overexpression of CLDN1 and CLDN10 indicates a favor-
able prognosis for overall survival in some patients with
lung adenocarcinoma. Cell-cell adhesion proteins play im-
portant roles in cellular transformation. Decreased claudin
1 and claudin 10 expression may lead to the compromised
tight Junctions’ function and the neoplasia progression.
Furthermore, it is postulated that claudins may also affect
cell signaling pathways. Expression of CLDN10 may be
regulated by the c-fos pathway, which is related with lung
cancer progression.
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